Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
The present invention relates to a method of treating or preventing estrogen-sensitive tumors in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R 1 , R 2 , R 3 , R 4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.
1. A method of treating estrogen-sensitive tumours in a mammal in need thereof, said estrogen-sensitive tumours being selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids, comprising orally administering to said mammal a therapeutically effective amount of an estrogenic component selected from the group consisting of:
substances represented by the following formula in which formula R 1 , R 2 , R 3 , R 4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms;
precursors capable of liberating a substance according to the aforementioned formula which precursors are derivatives of the present estrogen substances, wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranyl; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue; and
mixtures of one or more of the aforementioned substances and/or precursors;
said method not comprising administration of a GnRH composition.
2. The method according to claim 1 , wherein no more than 3 of R 1 , R 2 , R 3 , R 4 are hydrogen atoms.
3. The method according to claim 1 , wherein R 3 represents a hydroxyl group or an alkoxy group.
4. The method according to claim 1 , wherein at least 3 of the groups R 1 , R 2 , R 3 and R 4 represent hydrogen atoms.
5. The method according claim 1 , wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 30 days.
6. The method according to claim 1 , wherein the method comprises oral, transdermal, intravenous or subcutaneous administration of the estrogenic component.
7. The method according to claim 1 , wherein the estrogenic component is administered in an amount of at least 1 μg per kg of bodyweight per day.
8. The method according to claim 1 , wherein the estrogen-sensitive tumours are selected from the group consisting of breast cancer and uterine cancer.
9. The method according to claim 1 , further comprising co-administration of an aromatase inhibitor.
10. A method of treating estrogen-sensitive tumours in a mammal in need thereof, said estrogen-sensitive tumours being selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids, comprising orally administering to said mammal a therapeutically effective amount of an estrogenic component as defined in claim 1 in combination with an aromatase inhibitor.
11. The method according to claim 10 , wherein no more than 3 of R 1 , R 2 , R 3 , R 4 are hydrogen atoms.
12. The method according to claim 10 , wherein R 3 represents a hydroxyl group or an alkoxy group.
13. The method according to claim 10 , wherein at least 3 of the groups R 1 , R 2 , R 3 and R 4 represent hydrogen atoms.
14. The method according claim 10 , wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 30 days.
15. The method according to claim 10 , wherein the method comprises oral, transdermal, intravenous or subcutaneous administration of the estrogenic component.
16. The method according to claim 10 , wherein the estrogenic component is administered in an amount of at least 1 μg per kg of bodyweight per day.
17. The method according to claim 10 , wherein the estrogen-sensitive tumours are selected from the group consisting of breast cancer and uterine cancer.
18. The method according to claim 10 , wherein the aromatase inhibitor is co-administered in an effective amount to suppress blood serum 17β-estradiol level to below 10 pg/ml.
19. A method of treating estrogen-sensitive tumours in a mammal in need thereof, said estrogen-sensitive tumours being selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids, comprising orally administering to said mammal a therapeutically effective amount of an estrogenic component as defined in claim 1 .
20. The method according to claim 19 , wherein no more than 3 of R 1 , R 2 , R 3 , R 4 are hydrogen atoms.
21. The method according to claim 19 , wherein R 3 represents a hydroxyl group or an alkoxy group.
22. The method according to claim 19 , wherein at least 3 of the groups R 1 , R 2 , R 3 and R 4 represent hydrogen atoms.
23. The method according to claim 19 , wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 30 days.
24. The method according to claim 19 , wherein the method comprises oral, transdermal, intravenous or subcutaneous administration of the estrogenic component.
25. The method according to claim 19 , wherein the estrogenic component is administered in an amount of at least 1 μg per kg of bodyweight per day.
26. The method according to claim 19 , wherein the estrogen-sensitive tumours are selected from the group consisting of breast cancer and uterine cancer.
27. The method according to claim 19 , comprising co-administration of an aromatase inhibitor.